Besides the lower TFAM levels seen in patients with neurological diseases, TFAM gene mutations or polymorphisms, primarily from two TFAM mutations, rs1937, and rs2306604, are also supposed to increase the risk of PD (Gaweda-Walerych et al., 2010; Gatt et al., 2013), AD (Günther et al., 2004; Zhang et al., 2011; Lillenes et al., 2017), and HD progression (Lillenes et al., 2017). This evidence concerns the gene TFAM and Alzheimer disease.